Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antineoplastons A10 and AS2-1 With Total Androgen Blockade in Stage III/IV Prostate Cancer
NCT00003517Phase 2Withdrawn
- Sponsor
- Burzynski Research Institute
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of antineoplaston A10, antineoplaston AS2-1 in prostate cancer (PCa), sponsored by Burzynski Research Institute. Status: withdrawn.
02
Drugs
antineoplaston A10antineoplaston AS2-1
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00003517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003517.